Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...

Researchers at Karolinska Institutet, led by Dr. Helin Norberg and Dr. Erik Norberg, have identified a previously unknown ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

The number one unmet need is that we don't have a good handle on who's at risk, because patients generally don't have too ...

TEDC1 and TEDC2, functions in generating centriolar triplet microtubules, and that this is crucial for the proper formation of centriolar subdomains and the stability of centrioles throughout the cell ...

Among those with a TBS score less than 6 and node-negative disease, 5-year OS was similar between those receiving AC and those who did not.